Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MC4R | P32245 | 11/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | RBP4 | P02753 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19403647 | 0.91 | AR (0.62) | ARMAPTTSHRMEN1ALDH1A1 | |
| SCHEMBL26331833 | 0.91 | AR (0.74) | ARMAPTTSHRMEN1ALDH1A1 | |
| SCHEMBL19403769 | 0.91 | AR (0.74) | ARMAPTTSHRMEN1ALDH1A1 | |
| SCHEMBL19403595 | 0.91 | AR (0.74) | ARMAPTTSHRMEN1ALDH1A1 | |
| SCHEMBL19403719 | 0.91 | AR (0.62) | ARMAPTTSHRMEN1ALDH1A1 | |
| SCHEMBL19403644 | 0.91 | AR (0.62) | ARMAPTTSHRMEN1ALDH1A1 | |
| SCHEMBL19403645 | 0.91 | AR (0.62) | ARMAPTTSHRMEN1ALDH1A1 | |
| SCHEMBL20673451 | 0.91 | AR (0.74) | ARMAPTTSHRMEN1ALDH1A1 | |
| SCHEMBL20657909 | 0.91 | AR (0.62) | ARMAPTTSHRMEN1ALDH1A1 | |
| SCHEMBL26327887 | 0.89 | AR (0.58) | ARMAPTTSHRMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | AR 1/4885MAPT 4362/4885TSHR 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.